Publications by authors named "Maria Ayers"

Claim this Profile
C
Comparison of Posttherapy 4- and 24-Hour [Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Maria Ayers

J Nucl Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Visually Calculated SUV (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to Lu-PSMA Therapy: Comparison with Quantitative SUV and Patient Outcomes.
Mina Swiha, Nathan Papa, Zahra Sabahi, Narjess Ayati, Nikeith John, Maria Ayers

J Nucl Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing Lu-PSMA-I&T Therapy.
Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, William Counter, Bao Ho, Maria Ayers

J Nucl Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Louise Emmett, Nikeith John, Sarennya Pathmanandavel, William Counter, Maria Ayers

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, Andrew O Yam, Peter Wilson, Maria Ayers

J Nucl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Value of Posttreatment Ga-PSMA-11 PET/CT and F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew O Yam, Peter Wilson, Maria Ayers

J Nucl Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis